ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Bupivacaine Extended-Release Liposome Injection Market Outlook, In‑Depth Analysis & Forecast to 2031
Published Date: October 2025
|
Report Code: QYRE-Auto-10L20096
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Bupivacaine Extended Release Liposome Injection Market Outlook In Depth Analysis Forecast to 2031
BUY CHAPTERS

Global Bupivacaine Extended-Release Liposome Injection Market Outlook, In‑Depth Analysis & Forecast to 2031

Code: QYRE-Auto-10L20096
Report
October 2025
Pages:120
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Pacira Pharmaceuticals
Jiangsu Hengrui Pharm

Bupivacaine Extended-Release Liposome Injection Market Size

The global Bupivacaine Extended-Release Liposome Injection market is projected to grow from US$ 357 million in 2024 to US$ 487 million by 2031, at a CAGR of 4.6% (2025-2031), driven by critical product segments and diverse end‑use applications, while evolving U.S. tariff policies introduce trade‑cost volatility and supply‑chain uncertainty.

Bupivacaine Extended-Release Liposome Injection Market

Bupivacaine Extended-Release Liposome Injection Market

Bupivacaine liposome injection is a special formulation that encapsulates the local anesthetic bupivacaine within liposomes. This delivery system allows for prolonged and controlled release of bupivacaine, thereby extending the duration of its anesthetic effect.
From a downstream perspective, Local Anesthesia accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
Bupivacaine Extended-Release Liposome Injection leading manufacturers including Pacira Pharmaceuticals, Jiangsu Hengrui Pharm, etc., dominate supply; the top five capture approximately % of global revenue, with Pacira Pharmaceuticals leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR  %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).

Report Includes:

This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global Bupivacaine Extended-Release Liposome Injection market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers—sales volume, revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation

Scope of Bupivacaine Extended-Release Liposome Injection Market Report

Report Metric Details
Report Name Bupivacaine Extended-Release Liposome Injection Market
Accounted market size in 2024 US$ 357 million
Forecasted market size in 2031 US$ 487 million
CAGR 4.6%
Base Year 2024
Forecasted years 2025 - 2031
Segment by Type
  • 133mg Per Vial
  • 266mg Per Vial
Segment by Application
  • Local Anesthesia
  • Postoperative Analgesia
  • Other
Sales by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Pacira Pharmaceuticals, Jiangsu Hengrui Pharm
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

  • Chapter 1: Defines the Bupivacaine Extended-Release Liposome Injection study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
  • Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
  • Chapter 3: Dissects the manufacturer landscape—ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves.
  • Chapter 4: Unlocks high margin product segments—compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
  • Chapter 5: Targets downstream market opportunities—evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
  • Chapter 6: North America—breaks down sales and revenue by Type, by Application and country, profiles key manufacturers and assesses growth drivers and barriers.
  • Chapter 7: Europe—analyses regional sales, revenue and market by Type, by Application and manufacturers, flagging drivers and barriers.
  • Chapter 8: Asia Pacific—quantifies sales and revenue by Type, by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas.
  • Chapter 9: Central & South America—measures sales and revenue by Type, by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges.
  • Chapter 10: Middle East and Africa—evaluates sales and revenue by Type, by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
  • Chapter 11: Profiles manufacturers in depth—details product specs, sales, revenue, margins; Top manufactures 2024 sales breakdowns by Product type, by Application, by sales region SWOT analysis, and recent strategic developments.
  • Chapter 12: Supply chain—analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles.
  • Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
  • Chapter 15: Actionable conclusions and strategic recommendations.
  • Why This Report:
  • Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
  • Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
  • Negotiate from strength with suppliers (Chapter 12) and customers (Chapter5) using cost and demand intelligence.
  • Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
  • Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
  • Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

FAQ for this report

How fast is Bupivacaine Extended-Release Liposome Injection Market growing?

Ans: The Bupivacaine Extended-Release Liposome Injection Market witnessing a CAGR of 4.6% during the forecast period 2025-2031.

What is the Bupivacaine Extended-Release Liposome Injection Market size in 2031?

Ans: The Bupivacaine Extended-Release Liposome Injection Market size in 2031 will be US$ 487 million.

Who are the main players in the Bupivacaine Extended-Release Liposome Injection Market report?

Ans: The main players in the Bupivacaine Extended-Release Liposome Injection Market are Pacira Pharmaceuticals, Jiangsu Hengrui Pharm

What are the Application segmentation covered in the Bupivacaine Extended-Release Liposome Injection Market report?

Ans: The Applications covered in the Bupivacaine Extended-Release Liposome Injection Market report are Local Anesthesia, Postoperative Analgesia, Other

What are the Type segmentation covered in the Bupivacaine Extended-Release Liposome Injection Market report?

Ans: The Types covered in the Bupivacaine Extended-Release Liposome Injection Market report are 133mg Per Vial, 266mg Per Vial

1 Study Coverage
1.1 Introduction to Bupivacaine Extended-Release Liposome Injection: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Bupivacaine Extended-Release Liposome Injection Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 133mg Per Vial
1.2.3 266mg Per Vial
1.3 Market Segmentation by Application
1.3.1 Global Bupivacaine Extended-Release Liposome Injection Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Local Anesthesia
1.3.3 Postoperative Analgesia
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Bupivacaine Extended-Release Liposome Injection Revenue Estimates and Forecasts 2020-2031
2.2 Global Bupivacaine Extended-Release Liposome Injection Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020--2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.3 Global Bupivacaine Extended-Release Liposome Injection Sales Estimates and Forecasts 2020-2031
2.4 Global Bupivacaine Extended-Release Liposome Injection Sales by Region
2.4.1 Sales Comparison: 2020 VS 2024 VS 2031
2.4.2 Historical and Forecasted Sales by Region (2020-2031)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2020-2031)
3 Competition by Manufacturers
3.1 Global Bupivacaine Extended-Release Liposome Injection Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2020-2025)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2024)
3.2 Global Bupivacaine Extended-Release Liposome Injection Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2020-2025)
3.2.2 Global Key Manufacturer Revenue Ranking (2023 vs. 2024)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2020 VS 2024)
3.3.2 Manufacturer-Level Price Trends (2020-2025)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Main Product Type Market Size by Manufacturers
3.5.1 133mg Per Vial Market Size by Manufacturers
3.6 Global Bupivacaine Extended-Release Liposome Injection Market Concentration and Dynamics
3.6.1 Global Market Concentration (CR5 and HHI)
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global Bupivacaine Extended-Release Liposome Injection Sales Performance by Type
4.1.1 Global Historical and Forecasted Sales by Type (2020-2031)
4.1.2 Global Sales Market Share by Type (2020-2031)
4.2 Global Bupivacaine Extended-Release Liposome Injection Revenue Trends by Type
4.2.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.2.2 Global Revenue Market Share by Type (2020-2031)
4.3 Global Average Selling Price (ASP) Trends by Type (2020-2031)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global Bupivacaine Extended-Release Liposome Injection Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2020-2031)
5.1.2 Global Sales Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Bupivacaine Extended-Release Liposome Injection Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.2.2 Revenue Market Share by Application (2020-2031)
5.3 Global Pricing Dynamics by Application (2020-2031)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application
6 North America
6.1 North America Sales Volume and Revenue (2020-2031)
6.2 North America Key Manufacturers Sales Revenue in 2024
6.3 North America Bupivacaine Extended-Release Liposome Injection Sales and Revenue by Type (2020-2031)
6.4 North America Bupivacaine Extended-Release Liposome Injection Sales and Revenue by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America Bupivacaine Extended-Release Liposome Injection Market Size by Country
6.6.1 North America Revenue by Country
6.6.2 North America Sales Trends by Country
6.6.3 US
6.6.4 Canada
6.6.5 Mexico
7 Europe
7.1 Europe Sales Volume and Revenue (2020-2031)
7.2 Europe Key Manufacturers Sales Revenue in 2024
7.3 Europe Bupivacaine Extended-Release Liposome Injection Sales and Revenue by Type (2020-2031)
7.4 Europe Bupivacaine Extended-Release Liposome Injection Sales and Revenue by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe Bupivacaine Extended-Release Liposome Injection Market Size by Country
7.6.1 Europe Revenue by Country
7.6.2 Europe Sales Trends by Country
7.6.3 Germany
7.6.4 France
7.6.5 U.K.
7.6.6 Italy
7.6.7 Russia
8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2020-2031)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2024
8.3 Asia-Pacific Bupivacaine Extended-Release Liposome Injection Sales and Revenue by Type (2020-2031)
8.4 Asia-Pacific Bupivacaine Extended-Release Liposome Injection Sales and Revenue by Application (2020-2031)
8.5 Asia-Pacific Bupivacaine Extended-Release Liposome Injection Market Size by Region
8.5.1 Asia-Pacific Revenue by Region
8.5.2 Asia-Pacific Sales Trends by Region
8.6 Asia-Pacific Growth Accelerators and Market Barriers
8.7 Southeast Asia
8.7.1 Southeast Asia Revenue by Country (2020 VS 2024 VS 2031)
8.7.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.8 China
8.9 Japan
8.10 South Korea
8.11 China Taiwan
8.12 India
9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2020-2031)
9.2 Central and South America Key Manufacturers Sales Revenue in 2024
9.3 Central and South America Bupivacaine Extended-Release Liposome Injection Sales and Revenue by Type (2020-2031)
9.4 Central and South America Bupivacaine Extended-Release Liposome Injection Sales and Revenue by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America Bupivacaine Extended-Release Liposome Injection Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2020-2031)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2024
10.3 Middle East and Africa Bupivacaine Extended-Release Liposome Injection Sales and Revenue by Type (2020-2031)
10.4 Middle East and Africa Bupivacaine Extended-Release Liposome Injection Sales and Revenue by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa Bupivacaine Extended-Release Liposome Injection Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Turkey
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 Pacira Pharmaceuticals
11.1.1 Pacira Pharmaceuticals Corporation Information
11.1.2 Pacira Pharmaceuticals Business Overview
11.1.3 Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Product Models, Descriptions and Specifications
11.1.4 Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.1.5 Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Sales by Product in 2024
11.1.6 Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Sales by Application in 2024
11.1.7 Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection Sales by Geographic Area in 2024
11.1.8 Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection SWOT Analysis
11.1.9 Pacira Pharmaceuticals Recent Developments
11.2 Jiangsu Hengrui Pharm
11.2.1 Jiangsu Hengrui Pharm Corporation Information
11.2.2 Jiangsu Hengrui Pharm Business Overview
11.2.3 Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Product Models, Descriptions and Specifications
11.2.4 Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Sales, Price, Revenue and Gross Margin (2020-2025)
11.2.5 Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Sales by Product in 2024
11.2.6 Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Sales by Application in 2024
11.2.7 Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection Sales by Geographic Area in 2024
11.2.8 Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection SWOT Analysis
11.2.9 Jiangsu Hengrui Pharm Recent Developments
12 Value Chain and Supply-Chain Analysis
12.1 Bupivacaine Extended-Release Liposome Injection Industry Chain
12.2 Bupivacaine Extended-Release Liposome Injection Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Bupivacaine Extended-Release Liposome Injection Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2020-2031)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Bupivacaine Extended-Release Liposome Injection Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 Bupivacaine Extended-Release Liposome Injection Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global Bupivacaine Extended-Release Liposome Injection Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
FEATURED COMPANIES
Pacira Pharmaceuticals
Jiangsu Hengrui Pharm
List of Tables
 Table 1. Global Bupivacaine Extended-Release Liposome Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Global Bupivacaine Extended-Release Liposome Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 3. Global Bupivacaine Extended-Release Liposome Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 4. Global Bupivacaine Extended-Release Liposome Injection Revenue by Region (2020-2025) & (US$ Million)
 Table 5. Global Bupivacaine Extended-Release Liposome Injection Revenue by Region (2026-2031) & (US$ Million)
 Table 6. Global Bupivacaine Extended-Release Liposome Injection Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Units)
 Table 7. Global Bupivacaine Extended-Release Liposome Injection Sales by Region (2020-2025) & (K Units)
 Table 8. Global Bupivacaine Extended-Release Liposome Injection Sales by Region (2026-2031) & (K Units)
 Table 9. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 10. Global Bupivacaine Extended-Release Liposome Injection Sales by Manufacturers (2020-2025) & (K Units)
 Table 11. Global Bupivacaine Extended-Release Liposome Injection Sales Share by Manufacturers (2020-2025)
 Table 12. Global Bupivacaine Extended-Release Liposome Injection Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 13. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Manufacturers (2020-2025)
 Table 14. Global Key Manufacturers’Ranking Shift (2023 vs. 2024) (Based on Revenue)
 Table 15. Global Bupivacaine Extended-Release Liposome Injection by Manufacturer Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Bupivacaine Extended-Release Liposome Injection as of 2024)
 Table 16. Global Bupivacaine Extended-Release Liposome Injection Average Gross Margin (%) by Manufacturer (2020 VS 2024)
 Table 17. Global Bupivacaine Extended-Release Liposome Injection Average Selling Price (ASP) by Manufacturers (2020-2025) & (US$/Unit)
 Table 18. Key Manufacturers Bupivacaine Extended-Release Liposome Injection Manufacturing Base and Headquarters
 Table 19. Global Bupivacaine Extended-Release Liposome Injection Market Concentration Ratio (CR5 and HHI)
 Table 20. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
 Table 21. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 22. Global Bupivacaine Extended-Release Liposome Injection Sales by Type (2020-2025) & (K Units)
 Table 23. Global Bupivacaine Extended-Release Liposome Injection Sales by Type (2026-2031) & (K Units)
 Table 24. Global Bupivacaine Extended-Release Liposome Injection Revenue by Type (2020-2025) & (US$ Million)
 Table 25. Global Bupivacaine Extended-Release Liposome Injection Revenue by Type (2026-2031) & (US$ Million)
 Table 26. Global Bupivacaine Extended-Release Liposome Injection ASP by Type (2020-2031) & (US$/Unit)
 Table 27. Technical Specifications by Key Product Type
 Table 28. Global Bupivacaine Extended-Release Liposome Injection Sales by Application (2020-2025) & (K Units)
 Table 29. Global Bupivacaine Extended-Release Liposome Injection Sales by Application (2026-2031) & (K Units)
 Table 30. Bupivacaine Extended-Release Liposome Injection High-Growth Sectors Demand CAGR (2024-2031)
 Table 31. Global Bupivacaine Extended-Release Liposome Injection Revenue by Application (2020-2025) & (US$ Million)
 Table 32. Global Bupivacaine Extended-Release Liposome Injection Revenue by Application (2026-2031) & (US$ Million)
 Table 33. Global Bupivacaine Extended-Release Liposome Injection ASP by Application (2020-2031) & (US$/Unit)
 Table 34. Top Customers by Region
 Table 35. Top Customers by Application
 Table 36. North America Bupivacaine Extended-Release Liposome Injection Growth Accelerators and Market Barriers
 Table 37. North America Bupivacaine Extended-Release Liposome Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 38. North America Bupivacaine Extended-Release Liposome Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 39. Europe Bupivacaine Extended-Release Liposome Injection Growth Accelerators and Market Barriers
 Table 40. Europe Bupivacaine Extended-Release Liposome Injection Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Europe Bupivacaine Extended-Release Liposome Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 42. Asia-Pacific Bupivacaine Extended-Release Liposome Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 43. Asia-Pacific Bupivacaine Extended-Release Liposome Injection Sales (K Units) by Country (2020 VS 2024 VS 2031)
 Table 44. Asia-Pacific Bupivacaine Extended-Release Liposome Injection Growth Accelerators and Market Barriers
 Table 45. Southeast Asia Bupivacaine Extended-Release Liposome Injection Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Central and South America Bupivacaine Extended-Release Liposome Injection Investment Opportunities and Key Challenges
 Table 47. Central and South America Bupivacaine Extended-Release Liposome Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 48. Middle East and Africa Bupivacaine Extended-Release Liposome Injection Investment Opportunities and Key Challenges
 Table 49. Middle East and Africa Bupivacaine Extended-Release Liposome Injection Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
 Table 50. Pacira Pharmaceuticals Corporation Information
 Table 51. Pacira Pharmaceuticals Description and Major Businesses
 Table 52. Pacira Pharmaceuticals Product Models, Descriptions and Specifications
 Table 53. Pacira Pharmaceuticals Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 54. Pacira Pharmaceuticals Sales Value Proportion by Product in 2024
 Table 55. Pacira Pharmaceuticals Sales Value Proportion by Application in 2024
 Table 56. Pacira Pharmaceuticals Sales Value Proportion by Geographic Area in 2024
 Table 57. Pacira Pharmaceuticals Bupivacaine Extended-Release Liposome Injection SWOT Analysis
 Table 58. Pacira Pharmaceuticals Recent Developments
 Table 59. Jiangsu Hengrui Pharm Corporation Information
 Table 60. Jiangsu Hengrui Pharm Description and Major Businesses
 Table 61. Jiangsu Hengrui Pharm Product Models, Descriptions and Specifications
 Table 62. Jiangsu Hengrui Pharm Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 63. Jiangsu Hengrui Pharm Sales Value Proportion by Product in 2024
 Table 64. Jiangsu Hengrui Pharm Sales Value Proportion by Application in 2024
 Table 65. Jiangsu Hengrui Pharm Sales Value Proportion by Geographic Area in 2024
 Table 66. Jiangsu Hengrui Pharm Bupivacaine Extended-Release Liposome Injection SWOT Analysis
 Table 67. Jiangsu Hengrui Pharm Recent Developments
 Table 68. Key Raw Materials Distribution
 Table 69. Raw Materials Key Suppliers
 Table 70. Critical Raw Material Supplier Concentration (2024) & Risk Index
 Table 71. Milestones in Production Technology Evolution
 Table 72. Distributors List
 Table 73. Market Trends and Market Evolution
 Table 74. Market Drivers and Opportunities
 Table 75. Market Challenges, Risks, and Restraints
 Table 76. Research Programs/Design for This Report
 Table 77. Key Data Information from Secondary Sources
 Table 78. Key Data Information from Primary Sources


List of Figures
 Figure 1. Bupivacaine Extended-Release Liposome Injection Product Picture
 Figure 2. Global Bupivacaine Extended-Release Liposome Injection Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. 133mg Per Vial Product Picture
 Figure 4. 266mg Per Vial Product Picture
 Figure 5. Global Bupivacaine Extended-Release Liposome Injection Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 6. Local Anesthesia
 Figure 7. Postoperative Analgesia
 Figure 8. Other
 Figure 9. Bupivacaine Extended-Release Liposome Injection Report Years Considered
 Figure 10. Global Bupivacaine Extended-Release Liposome Injection Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 12. Global Bupivacaine Extended-Release Liposome Injection Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Figure 13. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Region (2020-2031)
 Figure 14. Global Bupivacaine Extended-Release Liposome Injection Sales (2020-2031) & (K Units)
 Figure 15. Global Bupivacaine Extended-Release Liposome Injection Sales (CAGR) by Region (2020-2031) (K Units)
 Figure 16. Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Region (2020-2031)
 Figure 17. Top 5 and Top 10 Manufacturers Bupivacaine Extended-Release Liposome Injection Sales Volume Market Share in 2024
 Figure 18. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share Ranking (2024)
 Figure 19. Tier Distribution by Revenue Contribution (2020 VS 2024)
 Figure 20. 133mg Per Vial Revenue Market Share by Manufacturer in 2024
 Figure 21. 266mg Per Vial Revenue Market Share by Manufacturer in 2024
 Figure 22. Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Type (2020-2031)
 Figure 23. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Type (2020-2031)
 Figure 24. Global Bupivacaine Extended-Release Liposome Injection Sales Market Share by Application (2020-2031)
 Figure 25. Global Bupivacaine Extended-Release Liposome Injection Revenue Market Share by Application (2020-2031)
 Figure 26. North America Bupivacaine Extended-Release Liposome Injection Sales YoY (2020-2031) & (K Units)
 Figure 27. North America Bupivacaine Extended-Release Liposome Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 28. North America Top 5 Manufacturers Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) in 2024
 Figure 29. North America Bupivacaine Extended-Release Liposome Injection Sales Volume (K Units) by Type (2020- 2031)
 Figure 30. North America Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) by Type (2020 - 2031)
 Figure 31. North America Bupivacaine Extended-Release Liposome Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 32. North America Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 33. US Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 34. Canada Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 35. Mexico Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 36. Europe Bupivacaine Extended-Release Liposome Injection Sales YoY (2020-2031) & (K Units)
 Figure 37. Europe Bupivacaine Extended-Release Liposome Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 38. Europe Top 5 Manufacturers Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) in 2024
 Figure 39. Europe Bupivacaine Extended-Release Liposome Injection Sales Volume (K Units) by Type (2020-2031)
 Figure 40. Europe Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 41. Europe Bupivacaine Extended-Release Liposome Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 42. Europe Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 43. Germany Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 44. France Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 45. U.K. Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 46. Italy Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 47. Russia Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 48. Asia-Pacific Bupivacaine Extended-Release Liposome Injection Sales YoY (2020-2031) & (K Units)
 Figure 49. Asia-Pacific Bupivacaine Extended-Release Liposome Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 50. Asia-Pacific Top 8 Manufacturers Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) in 2024
 Figure 51. Asia-Pacific Bupivacaine Extended-Release Liposome Injection Sales Volume (K Units) by Type (2020- 2031)
 Figure 52. Asia-Pacific Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) by Type (2020- 2031)
 Figure 53. Asia-Pacific Bupivacaine Extended-Release Liposome Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 54. Asia-Pacific Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 55. Indonesia Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 56. Japan Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 57. South Korea Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 58. China Taiwan Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 59. India Bupivacaine Extended-Release Liposome Injection Revenue (2020-2031) & (US$ Million)
 Figure 60. Central and South America Bupivacaine Extended-Release Liposome Injection Sales YoY (2020-2031) & (K Units)
 Figure 61. Central and South America Bupivacaine Extended-Release Liposome Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 62. Central and South America Top 5 Manufacturers Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) in 2024
 Figure 63. Central and South America Bupivacaine Extended-Release Liposome Injection Sales Volume (K Units) by Type (2021-2031)
 Figure 64. Central and South America Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 65. Central and South America Bupivacaine Extended-Release Liposome Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 66. Central and South America Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 67. Brazil Bupivacaine Extended-Release Liposome Injection Revenue (2020-2025) & (US$ Million)
 Figure 68. Argentina Bupivacaine Extended-Release Liposome Injection Revenue (2020-2025) & (US$ Million)
 Figure 69. Middle East, and Africa Bupivacaine Extended-Release Liposome Injection Sales YoY (2020-2031) & (K Units)
 Figure 70. Middle East and Africa Bupivacaine Extended-Release Liposome Injection Revenue YoY (2020-2031) & (US$ Million)
 Figure 71. Middle East and Africa Top 5 Manufacturers Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) in 2024
 Figure 72. Middle East and Africa Bupivacaine Extended-Release Liposome Injection Sales Volume (K Units) by Type (2021-2031)
 Figure 73. South America Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) by Type (2020-2031)
 Figure 74. Middle East and Africa Bupivacaine Extended-Release Liposome Injection Sales Volume (K Units) by Application (2020-2031)
 Figure 75. Middle East and Africa Bupivacaine Extended-Release Liposome Injection Sales Revenue (US$ Million) by Application (2020-2031)
 Figure 76. GCC Countries Bupivacaine Extended-Release Liposome Injection Revenue (2020-2025) & (US$ Million)
 Figure 77. Turkey Bupivacaine Extended-Release Liposome Injection Revenue (2020-2025) & (US$ Million)
 Figure 78. Egypt Bupivacaine Extended-Release Liposome Injection Revenue (2020-2025) & (US$ Million)
 Figure 79. South Africa Bupivacaine Extended-Release Liposome Injection Revenue (2020-2025) & (US$ Million)
 Figure 80. Bupivacaine Extended-Release Liposome Injection Industry Chain Mapping
 Figure 81. Regional Bupivacaine Extended-Release Liposome Injection Manufacturing Base Distribution (%)
 Figure 82. Global Bupivacaine Extended-Release Liposome Injection Production Market Share by Region (2020-2031)
 Figure 83. Bupivacaine Extended-Release Liposome Injection Production Process
 Figure 84. Regional Bupivacaine Extended-Release Liposome Injection Production Cost Structure
 Figure 85. Channels of Distribution (Direct Vs Distribution)
 Figure 86. Bottom-up and Top-down Approaches for This Report
 Figure 87. Data Triangulation
 Figure 88. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$4900

This license allows only one user to access the PDF.
Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Bioinformatics Barcelona

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions